Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

BioNTech inaugurates first manufacturing plant for mRNA vaccines in Rwanda

STORY: BioNTech inaugurates first manufacturing plant for mRNA vaccines in Rwanda SHOOTING TIME: Dec. 18, 2023 DATELINE: Dec. 21, 2023 LENGTH: 0:02:34 LOCATION: Kigali CATEGORY: TECHNOLOGY/ECONOMY SHOTLIST: 1. various of the event 2. SOUNDBITES 1 (English) UGUR SAHIN, Co-founder and CEO of BioNTech 3. SOUNDBITES 2 (English) MOUSSA FAKI MAHAMAT, Chairperson of the African Union (AU) Commission STORYLINE: BioNTech, a leading biotechnology company, on Monday inaugurated its first manufacturing plant for mRNA vaccines in Africa in Rwanda's capital of Kigali. The inauguration comes after the German company signed deals in 2021 with Rwanda and the Institut Pasteur de Dakar in Senegal to set up manufacturing sites on the continent. The facility construction was launched last year. BioNTech indicated in a statement that it is on course to develop prophylactic mRNA vaccines targeting infectious diseases such as tuberculosis, malaria, and HIV, and is also focusing on diseases with epidemic and pandemic potential,

E

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection. Hiroyuki Okuzawa, President =Date:November 28, 2023, Place:Tokyo

E

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection. From left: Shoji Hirashima, Senior Managing Executive Officer; Hiroyuki Okuzawa, President; Wataru Takasaki, Managing Executive Officer. =Date:November 28, 2023, Place:Tokyo

E

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection

Press conference regarding Daiichi Sankyo mRNA vaccine "Daichirona intramuscular injection. From left: Shoji Hirashima, Senior Managing Executive Officer; Hiroyuki Okuzawa, President; Wataru Takasaki, Managing Executive Officer. =Date:November 28, 2023, Place:Tokyo

E

Nobel laureate Kariko underscores groundbreaking potential of mRNA technology

STORY: Nobel laureate Kariko underscores groundbreaking potential of mRNA technology DATELINE: Oct. 15, 2023 LENGTH: 00:01:32 LOCATION: SZEGED, Hungary CATEGORY: SCIENCE SHOTLIST: 1. various of the panel discussion STORYLINE: Biochemist Katalin Kariko, 2023 Nobel laureate in physiology or medicine, underscored the application potential of mRNA technology in a panel discussion at her alma mater, University of Szeged, on Thursday evening. Originally focused on cancer vaccines, mRNA's versatility has broadened to encompass various therapeutic applications, particularly in the rapidly evolving field of therapy drugs, she explained to an audience made up mostly of university students in response to a question from Xinhua. "Definitely, the messenger RNA (mRNA) as a therapy will be used for many, many applications, many different treatments, and therapies," she said. "Originally, you know the first ones of these companies such as BioNtech in 2008 were formed to make cancer vaccines, and they gained a lot of kn

E

HUNGARY-SZEGED-NOBEL LAUREATE-KATALIN KARIKO

(231014) -- SZEGED, Oct. 14, 2023 (Xinhua) -- Biochemist Katalin Kariko, 2023 Nobel laureate in physiology or medicine, talks to students during a panel discussion at the University of Szeged in Szeged, Hungary, Oct. 12, 2023. TO GO WITH "Nobel laureate Kariko underscores groundbreaking potential of mRNA technology" (Xinhua/Chen Hao)

E

HUNGARY-SZEGED-NOBEL LAUREATE-KATALIN KARIKO

(231014) -- SZEGED, Oct. 14, 2023 (Xinhua) -- Biochemist Katalin Kariko (1st R), 2023 Nobel laureate in physiology or medicine, talks to students during a panel discussion at the University of Szeged in Szeged, Hungary, Oct. 12, 2023. TO GO WITH "Nobel laureate Kariko underscores groundbreaking potential of mRNA technology" (Photo by Attila Volgyi/Xinhua)

E

Nobel laureate Katalin Kariko: determination key to success

STORY: Nobel laureate Katalin Kariko: determination key to success DATELINE: Oct. 14, 2023 LENGTH: 00:02:47 LOCATION: Budapest CATEGORY: SCIENCE SHOTLIST: 1. SOUNDBITE 1 (Hungarian): KATALIN KARIKO, 2023 Nobel laureate in Physiology or Medicine 2. SOUNDBITE 2 (English): KATALIN KARIKO, 2023 Nobel laureate in Physiology or Medicine 3. various of the press briefing STORYLINE: Nobel laureate biochemist Katalin Kariko, renowned for her pioneering work in mRNA-based vaccines that played a decisive role in combating the COVID-19 pandemic, highlighted the importance of determination in achieving scientific success during a press briefing at the Hungarian Academy of Sciences on Wednesday. SOUNDBITE 1 (Hungarian): KATALIN KARIKO, 2023 Nobel laureate in Physiology or Medicine "I'm not a genius: even in elementary school, my grades were only average fours. I even got four in conversation while half of the class got fives because they just remembered and repeated what they heard. I read Janos Selye (Hungarian-born Ca

E

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

University of Pennsylvania professor Drew Weissman arrives at the venue of a press conference at the university in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine jointly with his Hungarian research partner Katalin Kariko for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

Hungary's Katalin Kariko (L) and her American research partner Drew Weissman attend a press conference at the University of Pennsylvania in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

Kariko, Weissman win Nobel medicine prize for COVID mRNA vaccine work

Hungarian scientist Katalin Kariko arrives at the venue of a press conference at the University of Pennsylvania in Philadelphia, the United States, on Oct. 2, 2023, after being awarded this year's Nobel Prize in physiology or medicine jointly with her American research partner Drew Weissman for their work leading to the development of COVID-19 vaccines using a new messenger RNA technology.

E

2 scientists share 2023 Nobel Prize in Physiology or Medicine

STORY: 2 scientists share 2023 Nobel Prize in Physiology or Medicine DATELINE: Oct. 2, 2023 LENGTH: 0:01:53 LOCATION: Stockholm CATEGORY: HEALTH SHOTLIST: 1. SOUNDBITE (English): THOMAS PERLMANN, Secretary-General of the Nobel Assembly 2. various of the press conference 3. various of Nobel Forum STORYLINE: Two scientists, Katalin Kariko and Drew Weissman, won the 2023 Nobel Prize in Physiology or Medicine for their discoveries concerning nucleoside base modifications, the Nobel Committee announced on Monday. SOUNDBITE (English): THOMAS PERLMANN, Secretary-General of the Nobel Assembly "The Nobel Assembly at Karolinska Institute has today decided to award the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin Kariko and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19." Through their groundbreaking findings, which have fundamentally changed the understanding of how mRNA interacts with the human

E

China, Indonesia achieve fruitful results in bilateral cooperation

STORY: China, Indonesia achieve fruitful results in bilateral cooperation DATELINE: Nov. 14, 2022 LENGTH: 00:03:32 LOCATION: Jakarta CATEGORY: POLITICS/ECONOMY SHOTLIST: 1. various of projects 2. various of Jakarta-Bandung High-Speed Railway 3. SOUNDBITE 1 (Chinese): FAN SHAOJIE, Jakarta-Bandung HSR project department, China Railway Electrification Engineering Group 4. various of Indonesia Morowali Industrial Park (IMIP) 5. various of Indonesia Weda Bay Industrial Park (IWIP) 6. SOUNDBITE 2 (Chinese): ZHANG FAN, Head of IMIP 7. SOUNDBITE 3 (Chinese): HE XIAOZHEN, Head of IWIP 8. various of China's mRNA COVID-19 vaccine 9. SOUNDBITE 4 (English): ANDREAS DONNY, PT Etana Biotechnologies Indonesia 10. SOUNDBITE 5 (Chinese): YING BO, Founder of AbogenBio STORYLINE: China and Indonesia are both major developing countries and emerging economies. The two sides have extensive converging interests and broad space for cooperation. In recent years, the cooperation between the two countries has achieved fruitful resu

E

Indonesia approves emergency use of China's mRNA COVID-19 vaccine

STORY: Indonesia approves emergency use of China's mRNA COVID-19 vaccine DATELINE: Oct. 1, 2022 LENGTH: 0:01:17 LOCATION: Jakarta CATEGORY: HEALTH/MEDICINE SHOTLIST: 1. STANDUP (English): SUN LEI, Xinhua correspondent 2. various of press release 3. SOUNDBITE 1 (English): PENNY LUKITO, Head of Indonesia's Food and Drug Monitoring Agency (BPOM) 4. SOUNDBITE 2 (English): ANDREAS DONNY, PT Etana Biotechnologies Indonesia 5. various of mRNA vaccine 6. various of BPOM STORYLINE: The Indonesian food and drug administration (BPOM) has issued an emergency use authorization (EUA) for the mRNA-platform COVID-19 vaccine, AWcorna, developed by Chinese companies. STANDUP (English): SUN LEI, Xinhua correspondent "The Indonesian food and drug authority BPOM has authorized a China-made mRNA vaccine for emergency use in individuals 18 years of age or above, as either primary or booster dose." AWcorna is a SARS-CoV-2 mRNA vaccine developed by Suzhou Abogen Biosciences Co., Ltd. with the participation of Walvax Biotechnolog

E

GLOBALink | Biomedical firms whitelisted in Shanghai resume work

STORY: Biomedical firms whitelisted in Shanghai resume work DATELINE: May 25, 2022 LENGTH: 0:01:04 LOCATION: SHANGHAI, China CATEGORY: HEALTH SHOTLIST: 1. Fosun Kite Biotechnology Co., Ltd. 2. CanSino (Shanghai) Biological Research Co., Ltd. 3. SOUNDBITE 1 (Chinese): LIU QUAN, Associate director, CanSino (Shanghai) Biological Research Co., Ltd. 4. SOUNDBITE 2 (Chinese): WANG HAOMENG, Deputy general manager, CanSino (Shanghai) Biological Research Co., Ltd. STORYLINE: COVID-hit Shanghai has whitelisted some companies to support their resumption of work. Fosun Kite Biotechnology Co., Ltd. is among the first batch approved to resume operation. Production has fully restarted with 140 workers back to their positions. The factory produces Yescarta, a CAR-T therapy to treat certain types of large B-cell lymphoma. Shanghai subsidiary of Chinese vaccine developer CanSino Biologics Inc. has also resumed operation. The company gained approval to launch clinical trials for its experimental COVID-19 mRNA vaccine i

E

Japan Prize award ceremony

Katalin Kariko, senior vice president at BioNTech SE, poses for photos at an award ceremony in Tokyo on April 13, 2022, after she won the Japan Prize for pioneering research contributing to the development of mRNA COVID-19 vaccines. (Pool photo)

E

Japan Prize award ceremony

Katalin Kariko, senior vice president at BioNTech SE, addresses an award ceremony in Tokyo on April 13, 2022, after she won the Japan Prize for pioneering research contributing to the development of mRNA COVID-19 vaccines. (Pool photo)

E

Cyprus offers COVID-19 vaccine fourth dose to certain people

STORY: Cyprus offers COVID-19 vaccine fourth dose to certain people DATELINE: March 31, 2022 LENGTH: 0:00:55 LOCATION: Nicosia CATEGORY: HEALTH SHOTLIST: 1 various of the vaccination 2 various of the street views STORYLINE: Cyprus has started administering a booster dose of an mRNA (messenger ribonucleic acid) vaccine against COVID-19 among certain people. According to the Health Ministry, the fourth dose would be administered to people aged 80 and over, health professionals and to those living and working in nursing homes and assisted living facilities. Children over the age of 12 are also eligible for a third jab if six months have elapsed since the second dose. The booster dose will also be made available to people over 70 in the next few days. On Tuesday, Cyprus reported 5,089 new daily coronavirus infections, which was three times more than three weeks ago. As this round of infections shows no signs of receding, the government has extended the existing coronavirus measures until April 11. Xin

E

Moderna to request FDA's approval for vaccinating children aged under 6

STORY: Moderna to request FDA's approval for vaccinating children aged under 6 DATELINE: March 24, 2022 LENGTH: 00:01:24 LOCATION: Washington D.C. CATEGORY: HEALTH SHOTLIST: 1. various of American biotechnology company Moderna related footage STORYLINE: American biotechnology company Moderna said Wednesday it will request the U.S. Food and Drug Administration (FDA) to grant emergency use authorization for its COVID-19 vaccine for children aged under 6. The company will submit the request to the FDA, as well as the European Medicines Agency and other global regulators "in the coming weeks," said the company in a statement. The submission was based on tests of its COVID-19 vaccine, known as mRNA-1273, in children aged 6 months to under 2 years, and 2 years to under 6 years. The interim analysis showed a robust neutralizing antibody response in both age groups after a 25 microgram two-dose primary series of mRNA-1273 along with a favorable safety profile, according to the company. In the study, vaccine ef

E

SOUTH AFRICA-CAPE TOWN-AFRICAN NATIONS-COVID-19-MRNA VACCINE TECHNOLOGY

(220220) -- CAPE TOWN, Feb. 20, 2022 (Xinhua) -- WHO chief Tedros Adhanom Ghebreyesus (2nd R, front) visits a lab in Cape Town, South Africa, Feb. 12, 2022. Six African countries will be the first on the continent to receive the technology needed to produce mRNA (messenger ribonucleic acid) vaccines, the World Health Organization (WHO) said on Friday. TO GO WITH "Six African nations to get mRNA vaccine technology" (Photo by Xabiso Mkhabela/Xinhua)

E

SOUTH AFRICA-CAPE TOWN-AFRICAN NATIONS-COVID-19-MRNA VACCINE TECHNOLOGY

(220220) -- CAPE TOWN, Feb. 20, 2022 (Xinhua) -- Staff members work at a lab in Cape Town, South Africa, Feb. 12, 2022. Six African countries will be the first on the continent to receive the technology needed to produce mRNA (messenger ribonucleic acid) vaccines, the World Health Organization (WHO) said on Friday. TO GO WITH "Six African nations to get mRNA vaccine technology" (Photo by Xabiso Mkhabela/Xinhua)

E

Japan Prize awarded to developers of COVID-19 vaccines

Screenshot shows Katalin Kariko (R), senior vice president of BioN Tech SE of Germany, and Drew Weissman, professor at University of Pennsylvania School of Medicine, attending an online press conference on Jan. 25, 2022, after co-receiving this year's Japan Prize for their pioneering research contributing to the development of COVID-19 mRNA vaccines.

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (R) and Manager Director of Pfizer Puurs Luc Van Steenwinkel listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Workers pack vaccine doses during visit by King Philippe of Belgium at Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (3L) and Manager Director of Pfizer Puurs Luc Van Steenwinkel (2L) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Pfizer workers empty vaccine fridge during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Workers pack vaccine doses during visit by King Philippe of Belgium at Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium visits the fridges zone during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Pfizer workers empty vaccine fridge during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) visits the vaccine packaging area during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Workers pack vaccine doses during visit by King Philippe of Belgium at Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

Pfizer workers empty vaccine fridge during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium visits the fridges zone during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) and Manager Director of Pfizer Puurs, Luc Van Steenwinkel (R) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (3L) and Manager Director of Pfizer Puurs , Luc Van Steenwinkel (2L) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (R) and Manager Director of Pfizer Puurs Luc Van Steenwinkel (not seen) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (R) and Manager Director of Pfizer Puurs Luc Van Steenwinkel listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (L) listen the explanations on LNP (Lipid Nano Particle) SKID machine during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium visits the fridges zone during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech Vaccine Production Site - Puurs

King Philippe of Belgium (C) visits the vaccine packaging area during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, 30 March 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by STEPHANIE LECOCQ/POOL/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

King Philippe of Belgium (R) is welcomed by Manager Director of Pfizer Puurs Luc Van Steenwinkel (L) during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, March 30, 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

King Philippe of Belgium (R) is welcomed by Manager Director of Pfizer Puurs Luc Van Steenwinkel (L) during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, March 30, 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

King Philippe of Belgium (R) is welcomed by Manager Director of Pfizer Puurs Luc Van Steenwinkel (L) during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, March 30, 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

BELGIUM, PUURS, MAR. 30, 2021 - King Philippe / Filip of Belgium visits the Pfizer-BioNTech vaccine production site in Puurs. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/ Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

King Philippe of Belgium attends a meeting during a visit to the Pfizer-BioNTech vaccine production site in Puurs, Belgium, March 30, 2021. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)

E

King Philippe Visits Pfizer-BioNTech - Belgium

BELGIUM, PUURS, MAR. 30, 2021 - King Philippe / Filip of Belgium visits the Pfizer-BioNTech vaccine production site in Puurs. The pharmaceutical group Pfizer is finalizing its mRNA-type vaccine on this site. Pfizer is also unveiling its new SKID machine, which encapsulates the active substance of the vaccine in lipids to keep it functioning efficiently. Photo by Stephanie Lecocq/ Pool/Reporters/ABACAPRESS.COM (Credit:Reporters/ABACA/Kyodo News Images)